Immuno-Oncology Market - Global Forecast to 2022

The biotechnology and pharmaceutical companies are striving to achieve first mover advantage by launching new and most effective therapies. This therapy is expected to be a game-changing approach to treating cancer.

Currently, Immuno-oncology market has witnessed a high number of advancements. The competition between the players is intensifying. The biotechnology and pharmaceutical companies are striving to achieve first mover advantage by launching new and most effective therapies. This therapy is expected to be a game-changing approach to treating cancer.

The report “Immuno-Oncology Market, By Type [mAb (Naked, Conjugate), Cancer Vaccines, Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4)], By Application (Lung, Melanoma, Leukemia, Lymphoma) - Global Forecast to 2022” provides a detailed analysis of the current and future market scenario of the global Immuno-oncology market with a brief overview of the industry. The report also provides insight about the major drivers and challenges, along with the latest trends and developments impacting the industry growth. In addition, the report also highlights various opportunities available for growth of the global Immuno-oncology market.

According to this edition of the report, the Immuno-oncology market is anticipated to hit billions of dollars within the next 5-10 years. The report also provides the sales of major marketed Immuno-oncology drugs.

On the basis of type of product, the global Immuno-oncology market has been segmented into major product classes including monoclonal antibodies, therapeutic vaccines, and immune checkpoint inhibitors amongst others. According to the report, monoclonal antibodies segment was estimated to account for the largest share in 2016 due to rising prevalence of cancer & rising usage in a number of therapies (antibody-directed enzyme prodrug therapy and radio immunotherapy). Based on geography, the report divides the market into North America, Europe, and Asia-Pacific. In 2016, North America was estimated to account for the largest share.

Primarily, the Immuno-oncology market is dominated by Lung Cancer & Melanoma applications with several companies and academic institutions focusing on novel treatment approaches, thus making the major contribution to the global immuno-oncology market. The report provides the market analysis of major indications along with the forecast till 2022.

Moreover, a major focus has been on the ongoing clinical trials for the development of innovative products. In this context, we have provided information about the Immuno-oncology programs at various stages of clinical development. The study also provides a comprehensive overview of various aspects of the clinical trials in the Immuno-oncology market, such as phases, and product type. In addition, the report highlights the strategic collaborations amongst the players for enhancing their market share.

The latter part of the report discusses some of the prominent players in the Immuno-oncology market. Some of the key players dominant in the market are Amgen, Bristol-Myers Squibb, F. Hoffmann-La Roche, and Merck among others. A brief business overview of each player has been provided, along with their product and pipeline portfolios and recent developments.

Overall, Immuno-oncology is an important and rapidly emerging field, which deserves the attention it has been receiving in recent years; and thus the report will prove as a complete source of knowledge and analysis for clients and potential investors.

http://ww.biomarketgroup.com
Table of Contents
1. Analyst View
2. Research Methodology
3. Immuno-Oncology: Overview
4. Market Drivers & Challenges
   4.1 Drivers
      4.1.1 Increasing Cancer Incidences
      4.1.2 Immune Checkpoint Inhibitors Sales Driving the Market Growth
      4.1.3 Growing Geriatric Population
      4.1.4 High Healthcare Spending In Developed Economies
      4.1.5 Strong Pipeline
      4.1.6 Increasing Efficacy in a Wide Variety of Indications
      4.1.7 Burgeoning Approval and Uptake of Immuno-Oncology Products
   4.2 Challenges
      4.2.1 Patent Expiry of Top-Selling Drugs
      4.2.2 Increasing Number of Side-Effects Post Immunotherapy Treatments
      4.2.3 Sky-High Development Costs of Cancer Immunotherapies
      4.2.4 High Cost of Treatment
      4.2.5 Lack of Awareness
   4.3 Opportunities
      4.3.1 Opdivo and Keytruda Presents Significant Growth Opportunity
      4.3.2 Combination Therapies Could Lead to Substantial Increases in Survival
      4.3.3 CAR-T Therapies: The Future of Cancer Care
      4.3.4 Small Companies Offering Huge Opportunities for Next Generation Immunotherapies
5. Global Immuno-Oncology Market Outlook 2022
6. Global Immuno-Oncology Market, by Product Class
   6.1 Monoclonal Antibodies (mAbs)
      6.1.1 Naked Monoclonal Antibodies
         6.1.1.1 Avastin (Bevacizumab)
         6.1.1.2 Herceptin (Trastuzumab)
      6.1.2 Conjugated Monoclonal Antibodies
         6.1.2.1 ADCETRIS (Brentuximab vedotin)
         6.1.2.2 Kadcyla (Ado-trastuzumab emtansine/TDM-1)
      6.1.3 Bispecific Monoclonal Antibodies
         6.1.3.1 Blincyto (Blinatumomab)
      6.1.4 Others
   6.2 Therapeutic Vaccines
      6.2.1 Provenge
      6.2.2 Pediarix/Infanrix
   6.3 Immune Checkpoint Inhibitors
      6.3.1 CTLA-4 Inhibitors (Cytotoxic T-Lymphocyte-Associated Protein-4)
         6.3.1.1 Yervoy (Ipilimumab)
      6.3.2 PD-1 and PD-L1 Inhibitors (Programmed Death 1 and Programmed Death Ligand
         6.3.2.1 Opdivo (Nivolumab)
         6.3.2.2 Keytruda (Pembrolizumab)
   6.4 Others
7. Global Immuno-Oncology Market, By Major Indications
   7.1 Head & Neck Cancer
   7.2 Lung Cancer
   7.3 Melanoma
   7.4 Lymphoma
   7.5 Leukemia
   7.6 Others
8. Global Immuno-Oncology Market, By Geography
   8.1 North America
   8.2 Europe
   8.3 Asia-Pacific
9. Trends & Developments
   9.1 Lucrative Investment Trend
   9.2 Emergence of Targeted and Combination Therapies
   9.3 NSCLC & Melanoma Showing Greatest Contributions to the IO Market
   9.4 Bristol-Myers Squibb and Merck & Co: Top Immuno-Oncology Dealmakers
10. Strategic Collaborations & Alliances in the Immuno-Oncology Industry
11. Pipeline Analysis of Immuno-Oncology
12. Competitive Landscape
   12.1 Share of Major Players
13. Key Players Analysis
   13.1 F. Hoffmann-La Roche AG
   13.2 Johnson & Johnson
   13.3 Amgen Inc.
   13.4 Celgene Corporation
   13.5 Bristol-Myers Squibb
   13.6 Merck & Co., Inc.
   13.7 Novartis
   13.8 AstraZeneca Plc
   13.9 Pfizer Inc

http://ww.biomarketgroup.com
List of Figures:

Figure 4-1: Global - Cancer Incidences (Million), 2015, 2020, 2025 & 2030
Figure 4-2: Global - Cancer Mortality (Million), 2015, 2020, 2025 & 2030
Figure 4-3: Global - Population above 60 Years (Billion), 2015 & 2050
Figure 5-1: Global - Immuno-Oncology Market (Billion US$), 2016-2022
Figure 6-1: Global - Share of Immuno-Oncology Market by Product (%), 2016
Figure 6-2: Global - Share of Immuno-Oncology Market by Product (%), 2022
Figure 6-3: Global - Monoclonal Antibodies Market (Billion US$), 2016-2022
Figure 6-4: Global - Avastin Market (Billion US$), 2012-2015
Figure 6-5: Global - Herceptin Market (Billion US$), 2012-2015
Figure 6-6: Global - ADCETRIS Market (Million US$), 2012-2015
Figure 6-7: Global - Kadriyta Market (Billion US$), 2013-2016
Figure 6-8: Global - Blincyto Market (Million US$), 2014-2016
Figure 6-9: Global - Other Monoclonal Antibodies Market (Billion US$), 2016-2022
Figure 6-10: Global - Therapeutic Cancer Vaccines Market (Billion US$), 2016-2022
Figure 6-11: Global - Provenge Market (Billion US$), 2012-2015
Figure 6-12: Global - Pediarix/Infanrix Market (Billion US$), 2012-2014
Figure 6-13: Global - Immune Checkpoint Inhibitors Market (Billion US$), 2016-2022
Figure 6-14: Global - Yervoy Market (Million US$), 2012-2015
Figure 6-15: Global - Opdivo Market (Billion US$), 2014-2016
Figure 6-16: Global - Keytruda Market (Billion US$), 2014-2016
Figure 6-17: Global - Others Market (Billion US$), 2016-2022
Figure 7-1: Global - Share of Immuno-Oncology Market by Application (%), 2016
Figure 7-2: Global - Share of Immuno-Oncology Market by Application (%), 2022
Figure 7-3: Global - Head & Neck Cancer Market (Billion US$), 2016-2022
Figure 7-4: Head & Neck Cancer - Immunotherapy Pipeline Analysis by Product (%), 2016
Figure 7-5: Head & Neck Cancer - Immunotherapy Pipeline Analysis by Phase (%), 2016
Figure 7-6: Global - Lung Cancer Market (Billion US$), 2016-2022
Figure 7-7: Lung Cancer - Immunotherapy Pipeline Analysis by Product (%), 2016
Figure 7-8: Lung Cancer - Immunotherapy Pipeline Analysis by Phase (%), 2016
Figure 7-9: Global - Melanoma Market (Billion US$), 2016-2022
Figure 7-10: Melanoma - Immunotherapy Pipeline Analysis by Product (%), 2016
Figure 7-11: Melanoma - Immunotherapy Pipeline Analysis by Phase (%), 2016
Figure 7-12: Global - Lymphoma Market (Billion US$), 2016-2022
Figure 7-13: Lymphoma - Immunotherapy Pipeline Analysis by Product (%), 2016
Figure 7-14: Lymphoma - Immunotherapy Pipeline Analysis by Phase (%), 2016
Figure 7-15: Global - Leukemia Market (Billion US$), 2016-2022
Figure 7-16: Leukemia - Immunotherapy Pipeline Analysis by Product (%), 2016
Figure 7-17: Leukemia - Immunotherapy Pipeline Analysis by Phase (%), 2016
Figure 7-18: Global - Other Cancer Market (Billion US$), 2016-2022
Figure 7-19: Other Cancer - Immunotherapy Pipeline Analysis by Product (%), 2016
Figure 7-20: Other Cancer - Immunotherapy Pipeline Analysis by Phase (%), 2016
Figure 8-1: Global - Share of Immuno-Oncology Market by Geographic Regions (%), 2016
Figure 8-2: Global - Share of Immuno-Oncology Market by Geographic Regions (%), 2022
Figure 8-3: North America - Immuno-Oncology Market (Billion US$), 2016-2022
Figure 8-4: Europe - Immuno-Oncology Market (Billion US$), 2016-2022
Figure 8-5: Asia-Pacific - Immuno-Oncology Market (Billion US$), 2016-2022
Figure 9-1: Immuno-Oncology Funding by Product Type
Figure 9-2: Major Investors in Immuno-Oncology Market
Figure 9-3: Bristol-Myers Squibb and Merck & Co. - Strategic Collaborations
Figure 11-1: Global - Immuno-Oncology Pipeline Analysis by Product Type (%), 2016
Figure 11-2: Global - Immuno-Oncology Pipeline Analysis by Phase (%), 2016
Figure 12-1: Global - Share of Key Players in Immuno-Oncology Market (%), 2015
Figure 13-1: F. Hoffmann-La Roche AG - Sales by Business Segments (%), 2015
Figure 13-2: F. Hoffmann-La Roche AG - Pharmaceuticals Division Sales by Segments (%), 2015
Figure 13-3: F. Hoffmann-La Roche AG - Pharmaceuticals Division Sales by Geography (%), 2015
Figure 13-4: Johnson & Johnson - Sales by Business Segments (%), 2015
Figure 13-5: Johnson & Johnson - Sales by Pharmaceutical Segments (%), 2015
Figure 13-6: Johnson & Johnson - Sales by Geography (%), 2015
Figure 13-7: Amgen Inc. - Sales by Product (%), 2015
Figure 13-8: Amgen Inc. - Sales by Geography (%), 2015
Figure 13-9: Celgene Corporation - Sales by Products (%), 2015
Figure 13-10: Bristol Myers Squibb - Revenue by Business Segments (%), 2015
Figure 13-11: Bristol Myers Squibb - Oncology Division Revenue by Segments (%), 2015
Figure 13-12: Bristol Myers Squibb - Revenue by Geography (%), 2015
Figure 13-13: Merck & Co., Inc. - Revenue by Business Segments (%), 2015
Figure 13-14: Merck & Co., Inc. - Pharmaceutical Division Revenue by Segments (%), 2015
Figure 13-15: Merck & Co., Inc. - Revenue by Geography (%), 2015
Figure 13-16: Novartis - Sales by Business Segment
Order by Fax - using the form below

Order by Post - print the order form below and send to:
  BioMarket Group
  Björnnäsvägen 21
  11419 STOCKHOLM
  SWEDEN
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to +46-8-56849191. If you have any questions please visit http://www.biomarketgroup.com/market-research-report/contacts/

Order Information
Please verify that the product information is correct:

Product Name: Immuno-Oncology Market - Global Forecast to 2022
Format: PDF
Price: 3000 USD (Single User License)

Delivery of hard copy or CD-ROM is subject to a Courier charge of 50 USD. Delivery within Sweden is subject to VAT at 25%.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: ____________________________
Name: ____________________________
Email Address:* ________________________________
Job Title: ____________________________
Organization: ____________________________

EU companies must supply: VAT / BTW / MOMS
MWST / IVA / FPA number: ____________________________

Address: ____________________________
Zip Code: ____________________________
City: ____________________________
State: ____________________________
Country: ____________________________
Phone Number: ____________________________
Fax Number: ____________________________

Payment Information
Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card:
  American Express
  Master Card
  Visa

Cardholder Name: ____________________________
Expiry Date (MM/YY): ____________________________
Card Number: ____________________________
CVV Number: ____________________________

☐ Pay by check:
Please post the check, accompanied by this form, to:
BioMarket Group
Björnäsvägen 21
11419 STOCKHOLM
SWEDEN

☐ Pay by wire transfer: Please transfer funds to:
Account number: 43521169
Swift code: HANDSESS
IBAN number: SE74 6000 0000 0000 4352 1169
Bank Address: Handelsbanken, Stockholm, Sweden

If you have a Marketing Code please enter it below:
Marketing Code: ____________________________

Please supply purchase order number if needed: ____________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, Gmail)

Please note that by ordering from BioMarket Group you are agreeing to our Terms and Conditions at http://www.biomarketgroup.com/market-research-report/biomarket-group-full-terms-and-conditions/

Please fax this form to: +46-8-56849191